-
-
公开(公告)号：JPH06321803A
公开(公告)日：1994-11-22
申请号：JP13906693
申请日：1993-05-17
申请人： KIRIN BREWERY
发明人： SAKURAI HIROSHI
IPC分类号： A61K9/00 , A61K38/00 , A61K38/21 , A61K38/22 , A61K38/23 , A61K38/27 , A61K38/28 , A61K47/34 , A61K47/36 , A61K47/42 , A61K37/24 , A61K37/02 , A61K37/26 , A61K37/30 , A61K37/36 , A61K37/66
摘要： PURPOSE:To obtain an embedding type gradually releasing preparation which can decrease the needed frequency for water-soluble peptide hormone administration. CONSTITUTION:This embedding type gradually releasing preparation comprises a cylinder less than 10mm in outer diameter which is made of essentially water- insoluble polymer biodegradable in vivo and has at least one open end and a core material to be placed in the cylinder containing water-soluble protein having a physiological activity. The preparation has the following features: it can gradually release the embedded drug for a long period of time from several days to about 1 month, (2) the material of the cylinder is biocompatible and biodegradable and gradually decomposed after releasing, thus it is in no need of extraction and (3) the mechanism of gradual release of water-soluble protein largely depends on wetting of the cylinder with body fluid from the open end and diffusion rate of the drug in the cylinder and the releasing speed can be controlled by selection of the shape of the cylinder and the kind of the polymer.
-
公开(公告)号：JPH06298666A
公开(公告)日：1994-10-25
申请号：JP8636993
申请日：1993-04-13
申请人： TORAY INDUSTRIES
摘要： PURPOSE:To obtain a treating agent effective for protecting the disorder of hematopoietic cell against the marrow suppression caused by chemotherapy or radiotherapy and preventing the decrease in leukocytes and platelets by using an interferon as an active component. CONSTITUTION:The agent contains an interferon as a main component. The interferon is properly compounded with pharmaceutical additives such as human serum albumin, gelatin, mannitol, sorbitol, lactose, trehalose and surfactant as other components and prepared in the form of a pharmaceutical preparation. The daily dose of the agent is 10-100,000,000 units per 1kg body-weight. The interferon to be used in the agent is obtained by purifying an interferon produced from an interferon-producing cell or by a gene recombination technique.
-
公开(公告)号：JPH06271478A
公开(公告)日：1994-09-27
申请号：JP6418893
申请日：1993-03-23
申请人： OTSUKA PHARMA CO LTD
发明人： TSUBOTA KAZUO , SAITO ICHIRO , HAMAMOTO MITSUO
摘要： PURPOSE:To obtain the subject treating agent for ophthalmic field effective for the treatment of dry eye and its relating diseases, etc., such as lowering of lacrimation and Sjogren's syndrome. CONSTITUTION:The objective treating agent contains an interferon (preferably interferon-alpha, etc.) as an active component and a stabilizer (e.g. human serum albumin and sugar), a disinfectant (e.g. benzalkonium chloride), a buffering agent (e.g. boric acid and phosphoric acid), a chelating agent, etc., as arbitrary components.
-
公开(公告)号：JPH06503354A
公开(公告)日：1994-04-14
申请号：JP50080593
申请日：1992-06-19
-
-
-
-
公开(公告)号：JPH05255396A
公开(公告)日：1993-10-05
申请号：JP1826292
申请日：1992-01-07
IPC分类号： A61K38/00 , A61K38/21 , A61K38/22 , A61P7/00 , A61P7/04 , C07K1/20 , C07K1/22 , C07K14/435 , C07K14/52 , C07K14/54 , C12N15/09 , C12N15/24 , C12P21/02 , C12R1/91 , C07K15/06 , A61K37/02 , A61K37/24 , A61K37/66
摘要： PURPOSE:To provide an IL-11-like protein as a magakaryocyte potentiator having strong action in an amount enough to be used as a medicine. CONSTITUTION:An interleukin 11-like protein having about 25,000 molecular weight by gel filtration method, about 23,000 molecular weight by SDS-PAGE, an isoelectric point of pI>9 and no megakaryocyte colony stimulating factor activity. The protein is produced by cell culture technology and manufactured in a large amount by adding an interleukin 11-like protein formation promotor to a medium. The interleukin 11-like protein activates megakaryocyte potentiator, increases blood platelet in peripheral blood and has stronger actions than those of known factors and is effective for preventing and treating thrombocytopenia.
-
公开(公告)号：JPH02264730A
公开(公告)日：1990-10-29
申请号：JP8632089
申请日：1989-04-04
申请人： TAIRA MITSUTOSHI , SHIONOGI & CO
发明人： TAIRA MITSUTOSHI
IPC分类号： A61K9/12 , A61K9/00 , A61K9/72 , A61K38/21 , A61K47/26 , A61K47/42 , A61P35/02 , A61P43/00 , A61K37/66
摘要： PURPOSE:To treat ATLL while reducing side effects by dissolving or suspending a therapeutically effective amount of interferon-gamma (IFN-gamma) in an aqueous medium and subsequently administering the prepared solution or suspension transtracheally in a fine-foggy state. CONSTITUTION:IFN-gamma (preferably gene recombinated human IFN-gamma) as a main ingredient is mixed with serum albumin or a surfactant, maltose and a buffer solution (preferably having a buffering range on the pH of 6.5-7.5), and the prepared mixture is dissolved in distilled water for injection and/or physiological saline to prepare a substantially neutral l inhalent, which is inhalent with a nebutizer to treat ATLL (adult T cell leukemia.lymphoma). A dose of 100000-6000000 JRU as the IFU-gamma is dissolved in 5-30ml of physiological saline and subsequently inhaled over several min - several ten min. The addition of serum albumin or a surfactant to the inhalant improves the solubility and the stability of the IFN-gamma when stored.
-
-
-
-
-
-
-
-
-
搜索结果
64 条记录 (耗时 0.012 秒)
